Philip Mor­ris nabs over 20% of Vec­tura's shares; On­copep­tides drug may be head­ed for ad­comm, CEO says

About a week af­ter Vec­tura’s board of di­rec­tors said they would unan­i­mous­ly back a Philip Mor­ris takeover, the to­bac­co gi­ant now has con­trol of more than a fifth of the res­pi­ra­to­ry drug­mak­er’s shares.

Share­hold­ers with 22.61% of Vec­tura’s shares have ten­dered their stock to Philip Mor­ris, Reuters re­port­ed on Wednes­day. The move is part of the cig­a­rette com­pa­ny’s $1.5 bil­lion bid to buy Vec­tura. Philip Mor­ris, best known for its Marl­boro prod­ucts, of­fered 165 pence per share, beat­ing out a 155 pence per share of­fer by the pri­vate eq­ui­ty firm The Car­lyle Group.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.